Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner
Article first published online: 3 AUG 2004
Copyright © 2004 John Wiley & Sons, Ltd.
Journal of Applied Toxicology
Volume 24, Issue 4, pages 269–275, July/August 2004
How to Cite
Özyurt, H., Yıldırım, Z., Kotuk, M., Yılmaz, H. R., Yağmurca, M., Iraz, M., Söğüt, S. and Gergerlioglu, S. (2004), Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner. J. Appl. Toxicol., 24: 269–275. doi: 10.1002/jat.983
- Issue published online: 3 AUG 2004
- Article first published online: 3 AUG 2004
- Manuscript Revised: 15 APR 2004
- Manuscript Accepted: 15 APR 2004
- Manuscript Received: 27 FEB 2004
- renal failure;
The aim of this study was to investigate the optimum dosage of erdosteine to ameliorate cisplatin-induced nephrotoxicity. Three different doses of erdosteine at 25, 50 and 75 mg kg−1 were studied in rats. Intraperitoneal administration of 7 mg kg−1 cisplatin led to acute renal failure, as indicated by kidney histology and increases in plasma creatinine and blood urea nitrogen (BUN) levels. At 5 days after cisplatin injection the BUN level was increased signiﬁcantly from 15.1 ± 4.3 to 126.7 ± 152.6 mg dl−1 and plasma creatinine levels increased from 0.37 ± 0.005 to 1.68 ± 1.9 mg dl−1. When the rats were administered 50 and 75 mg kg−1 erdosteine 24 h before cisplatin injection that was continued until sacriﬁce (total of 6 days), the BUN and creatinine levels remained similar to control levels and the grade of histology was similar. Erdosteine at doses of 50 and 75 mg kg−1 ameliorates cisplatin-induced renal failure. The optimum dose of erdosteine may be 50 mg kg−1 in this study. Copyright © 2004 John Wiley & Sons, Ltd.